Targeting metabolic plasticity to overcome chemotherapy resistance in acute myeloid leukemia (A03)

• Subject Area: Hematology, Oncology
• Term: since 2025
• Project identifier: Deutsche Forschungsgemeinschaft (DFG) - Project number 533056198

Project A03 will identify key metabolic features (e.g., OXPHOS, FAO, glycolysis, ROS, etc.) of primary AML cells that survived chemotherapy using metabolic spectral flow cytometry. Bone marrow organoids will be established to analyze metabolic adaptation of AML and niche cells under cytotoxic stress caused by clinically approved compounds. Single cell multi-omics, able to simultaneously determine metabolic properties, transcriptome and surface proteome will be applied in order to identify targetable vulnerabilities upon metabolic adaptation.

• DFG Programme: Collaborative Research Centres
• Subproject of: SFB 1709: Cellular Plasticity in Myeloid Malignancies: From Mechanisms to Therapies
• Applicant Institution: Ruprecht-Karls-Universität Heidelberg
• Project Head: Privatdozent Dr. Simon Raffel